Economic assessment of eltrombopag in the treatment of thrombocytopenia

Federica Romano, Matteo Ruggeri, Silvia Coretti, Edoardo Giovanni Giannini, Dario Sacchini, Brigida Eleonora Annichiarico, Marco Marchetti, Francesco Rodeghiero, Dario Lidonnici

Research output: Contribution to journalArticlepeer-review


Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.

Original languageEnglish
Pages (from-to)713-720
Number of pages8
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number4
Publication statusPublished - 2015


  • Cost-effectiveness
  • Markov model
  • Revolade
  • Sensitivity analysis
  • Thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy


Dive into the research topics of 'Economic assessment of eltrombopag in the treatment of thrombocytopenia'. Together they form a unique fingerprint.

Cite this